Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme
- PMID: 28507382
Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme
Abstract
Focus of brain tumour research is shifting towards tumour genesis and genetics, and possible development of individualized treatment plans. Genetic analysis shows recurrent mutation in isocitrate dehydrogenase (IDH1) gene in most Glioblastoma multiforme (GBM) cells. In this review we evaluated the prognostic significance of IDH 1 mutation on the basis of published evidence. Multiple retrospective clinical analyses correlate the presence of IDH1 mutation in GBM with good prognostic outcomes compared to wild-type IDH1. A systematic review reported similar results. Based on the review of current literature IDH1 mutation is an independent factor for longer overall survival (OS) and progression free survival (PFS) in GBM patients when compared to wild-type IDH1. The prognostic significance opens up new avenues for treatment.
Keywords: Glioblastoma multiforme, IDH1 mutation, overall survival, progression free survival.
Similar articles
-
Isocitrate dehydrogenase-1 mutations as prognostic biomarker in glioblastoma multiforme patients in West Bohemia.Biomed Res Int. 2014;2014:735659. doi: 10.1155/2014/735659. Epub 2014 Jan 9. Biomed Res Int. 2014. PMID: 24511544 Free PMC article.
-
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.Clin Neurol Neurosurg. 2016 Dec;151:31-36. doi: 10.1016/j.clineuro.2016.10.004. Epub 2016 Oct 12. Clin Neurol Neurosurg. 2016. PMID: 27764705
-
IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.Gene. 2015 Jan 1;554(1):81-6. doi: 10.1016/j.gene.2014.10.027. Epub 2014 Oct 14. Gene. 2015. PMID: 25455102
-
[Isocitrate dehydrogenase type I mutation as a prognostic factor in glioblastoma and a literature review].Neurocirugia (Astur). 2015 Nov-Dec;26(6):276-83. doi: 10.1016/j.neucir.2015.04.001. Epub 2015 Jul 18. Neurocirugia (Astur). 2015. PMID: 26194445 Review. Spanish.
-
The prognostic significance of CDKN2A homozygous deletion in IDH-mutant lower-grade glioma and glioblastoma: a systematic review of the contemporary literature.J Neurooncol. 2020 Jun;148(2):221-229. doi: 10.1007/s11060-020-03528-2. Epub 2020 May 8. J Neurooncol. 2020. PMID: 32385699
Cited by
-
Integrated Gene Expression Data-Driven Identification of Molecular Signatures, Prognostic Biomarkers, and Drug Targets for Glioblastoma.Biomed Res Int. 2024 Aug 16;2024:6810200. doi: 10.1155/2024/6810200. eCollection 2024. Biomed Res Int. 2024. PMID: 39184354 Free PMC article.
-
Current Role of Laser Interstitial Thermal Therapy in the Treatment of Intracranial Tumors.Asian J Neurosurg. 2020 Dec 21;15(4):800-808. doi: 10.4103/ajns.AJNS_185_20. eCollection 2020 Oct-Dec. Asian J Neurosurg. 2020. PMID: 33708647 Free PMC article. Review.
-
Radiogenomic Predictors of Recurrence in Glioblastoma-A Systematic Review.J Pers Med. 2022 Mar 4;12(3):402. doi: 10.3390/jpm12030402. J Pers Med. 2022. PMID: 35330402 Free PMC article. Review.
-
NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis.Oncotarget. 2017 Aug 28;8(59):99514-99530. doi: 10.18632/oncotarget.20577. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29245920 Free PMC article.
-
Diffusion Tensor Imaging Reveals Microstructural Heterogeneity of Normal-Appearing White Matter and Related Cognitive Dysfunction in Glioma Patients.Front Oncol. 2019 Jun 26;9:536. doi: 10.3389/fonc.2019.00536. eCollection 2019. Front Oncol. 2019. PMID: 31293974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Miscellaneous